SIMILAR PATTERNS OF AMINO ACIDS FOR 2F81_A_017A302_2

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1czi	CHYMOSIN (Bos taurus)	PF00026 (Asp)	5	ASP E 215 GLY E 217 VAL E 222 GLY E 76 ILE E 300	None	0.75A	2f81B-1cziE: 6.7	2f81B-1cziE: 17.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1czi	CHYMOSIN (Bos taurus)	PF00026 (Asp)	5	LEU E 30 ASP E 32 GLY E 34 ASP E 37 ILE E 120	None	0.59A	2f81B-1cziE: 6.7	2f81B-1cziE: 17.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 GLY A 48 VAL A 82 ILE A 84	A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 (-4.1A) A79 A 800 (-4.5A) A79 A 800 (-3.8A)	0.66A	2f81B-1hvcA: 14.0	2f81B-1hvcA: 46.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.1A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.9A) A79 A 800 (-4.5A) A79 A 800 (-3.6A)	0.62A	2f81B-1hvcA: 14.0	2f81B-1hvcA: 46.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	A79 A 800 ( 4.0A) A79 A 800 (-2.8A) A79 A 800 (-3.0A) A79 A 800 (-3.2A) A79 A 800 (-2.7A) A79 A 800 ( 4.7A) A79 A 800 ( 4.3A) A79 A 800 (-3.4A) A79 A 800 ( 4.0A) A79 A 800 ( 3.4A) A79 A 800 (-4.5A) A79 A 800 (-3.8A)	0.44A	2f81B-1hvcA: 14.0	2f81B-1hvcA: 46.31
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1hvc	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	A79 A 800 ( 3.8A) A79 A 800 (-2.7A) A79 A 800 (-3.0A) A79 A 800 (-3.1A) A79 A 800 (-2.8A) A79 A 800 ( 4.9A) A79 A 800 ( 4.4A) A79 A 800 ( 3.7A) A79 A 800 (-3.8A) A79 A 800 (-4.5A) A79 A 800 (-3.6A)	0.42A	2f81B-1hvcA: 14.0	2f81B-1hvcA: 46.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1hyl	HYPODERMA LINEATUM COLLAGENASE (Hypoderma lineatum)	PF00089 (Trypsin)	5	LEU A 209 ALA A 136 GLY A 183 VAL A 231 ILE A 210	None	0.93A	2f81B-1hylA: undetectable	2f81B-1hylA: 20.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1j2b	ARCHAEOSINE TRNA-GUANINE TRANSGLYCOSYLASE (Pyrococcus horikoshii)	PF01472 (PUA) PF01702 (TGT) PF14809 (TGT_C1) PF14810 (TGT_C2)	5	ASP A 535 GLY A 537 ASP A 542 GLY A 449 PRO A 504	None	0.78A	2f81B-1j2bA: undetectable	2f81B-1j2bA: 11.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1kae	HISTIDINOL DEHYDROGENASE (Escherichia coli)	PF00815 (Histidinol_dh)	5	GLY A 227 ALA A 228 ASP A 204 GLY A 196 ILE A 206	None	0.82A	2f81B-1kaeA: undetectable	2f81B-1kaeA: 13.46
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1l3i	PRECORRIN-6Y METHYLTRANSFERASE/PU TATIVE DECARBOXYLASE (Methanothermobacter thermautotrophicus)	PF13847 (Methyltransf_31)	5	LEU A 136 GLY A 108 VAL A 179 GLY A 15 ILE A 135	None SAH A 801 (-3.4A) None SAH A 801 ( 3.8A) None	0.89A	2f81B-1l3iA: undetectable	2f81B-1l3iA: 20.62
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1lk5	D-RIBOSE-5-PHOSPHATE ISOMERASE (Pyrococcus horikoshii)	PF06026 (Rib_5-P_isom_A)	5	GLY A 101 ALA A 102 GLY A 207 ILE A 97 ILE A 179	CL A1001 (-3.4A) None None None None	0.98A	2f81B-1lk5A: undetectable	2f81B-1lk5A: 20.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1prs	DEVELOPMENT-SPECIFIC PROTEIN S (Myxococcus xanthus)	PF00030 (Crystall)	5	LEU A 19 GLY A 22 VAL A 44 VAL A 6 ILE A 4	None	0.92A	2f81B-1prsA: undetectable	2f81B-1prsA: 23.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1q9p	HIV-1 PROTEASE (Homo sapiens)	PF00077 (RVP)	7	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.56A	2f81B-1q9pA: 10.0	2f81B-1q9pA: 98.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.20A	2f81B-1sivA: 18.5	2f81B-1sivA: 50.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	None	0.37A	2f81B-1sivA: 18.5	2f81B-1sivA: 50.98
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1siv	SIV PROTEASE (Simian immunodeficiency virus)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 ILE A 84	None	0.38A	2f81B-1sivA: 18.5	2f81B-1sivA: 50.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1tjr	BX1 (Zea mays)	PF00290 (Trp_syntA)	5	GLY A 307 ALA A 308 ASP A 309 VAL A 269 ILE A 303	None	0.84A	2f81B-1tjrA: undetectable	2f81B-1tjrA: 19.59
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1to6	GLYCERATE KINASE (Neisseria meningitidis)	PF02595 (Gly_kinase)	5	ALA A 190 ASP A 191 GLY A 244 ILE A 247 ILE A 259	None None SO4 A 373 (-3.5A) None None	0.81A	2f81B-1to6A: undetectable	2f81B-1to6A: 15.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1u2e	2-HYDROXY-6-KETONONA -2,4-DIENEDIOIC ACID HYDROLASE (Escherichia coli)	PF12697 (Abhydrolase_6)	5	LEU A 281 GLY A 61 ALA A 60 ILE A 54 VAL A 277	None	0.96A	2f81B-1u2eA: undetectable	2f81B-1u2eA: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1uww	ENDOGLUCANASE (Bacillus akibai)	PF03424 (CBM_17_28)	5	ALA A 122 VAL A 89 ILE A 169 VAL A 147 ILE A 149	None	0.96A	2f81B-1uwwA: undetectable	2f81B-1uwwA: 21.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1v5f	PYRUVATE OXIDASE (Aerococcus viridans)	PF00205 (TPP_enzyme_M) PF02775 (TPP_enzyme_C) PF02776 (TPP_enzyme_N)	5	ASP A 388 ALA A 444 ASP A 442 VAL A 466 ILE A 440	None TPP A1602 (-3.7A) MG A1603 ( 2.8A) None None	0.97A	2f81B-1v5fA: undetectable	2f81B-1v5fA: 10.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1wsv	AMINOMETHYLTRANSFERA SE (Homo sapiens)	PF01571 (GCV_T) PF08669 (GCV_T_C)	5	LEU A 152 VAL A 192 GLY A 166 VAL A 207 ILE A 205	LEU A 152 ( 0.6A) VAL A 192 ( 0.6A) GLY A 166 ( 0.0A) VAL A 207 ( 0.6A) ILE A 205 ( 0.4A)	0.88A	2f81B-1wsvA: undetectable	2f81B-1wsvA: 14.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1yg0	COP ASSOCIATED PROTEIN (Helicobacter pylori)	PF00403 (HMA)	5	GLY A 62 ALA A 61 ASP A 60 VAL A 23 ILE A 19	None	0.96A	2f81B-1yg0A: undetectable	2f81B-1yg0A: 19.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2cvj	THIOREDOXIN REDUCTASE RELATED PROTEIN (Thermus thermophilus)	PF00890 (FAD_binding_2) PF07992 (Pyr_redox_2)	5	LEU A 170 GLY A 24 ALA A 23 ASP A 177 VAL A 164	None	0.99A	2f81B-2cvjA: undetectable	2f81B-2cvjA: 16.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2dph	FORMALDEHYDE DISMUTASE (Pseudomonas putida)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	6	GLY A 174 ALA A 201 VAL A 189 GLY A 296 ILE A 297 ILE A 191	None	1.43A	2f81B-2dphA: undetectable	2f81B-2dphA: 14.51
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2e4u	METABOTROPIC GLUTAMATE RECEPTOR 3 (Rattus norvegicus)	PF01094 (ANF_receptor) PF07562 (NCD3G)	5	LEU A 86 GLY A 92 ASP A 77 ILE A 146 ILE A 79	None	0.90A	2f81B-2e4uA: undetectable	2f81B-2e4uA: 11.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ewn	BIRA BIFUNCTIONAL PROTEIN (Escherichia coli)	PF02237 (BPL_C) PF03099 (BPL_LplA_LipB) PF08279 (HTH_11)	5	GLY A 186 ALA A 185 GLY A 154 ILE A 153 ILE A 207	BTX A 501 (-3.3A) None None None None	0.74A	2f81B-2ewnA: undetectable	2f81B-2ewnA: 17.95
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fmb	EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE (Equine infectious anemia virus)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 55 PRO A 86 VAL A 87 ILE A 89	None LP1 A 201 (-2.3A) LP1 A 201 (-3.8A) LP1 A 201 (-3.5A) LP1 A 201 (-3.6A) None LP1 A 201 (-3.4A) LP1 A 201 (-3.9A) LP1 A 201 ( 4.9A) LP1 A 201 (-4.2A)	0.39A	2f81B-2fmbA: 15.0	2f81B-2fmbA: 33.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2g28	PYRUVATE DEHYDROGENASE E1 COMPONENT (Escherichia coli)	PF00456 (Transketolase_N)	5	LEU A 565 GLY A 573 PRO A 594 VAL A 516 ILE A 518	None	0.84A	2f81B-2g28A: undetectable	2f81B-2g28A: 8.09
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ri6	2-HYDROXY-6-OXO-6-PH ENYLHEXA-2,4-DIENOAT E HYDROLASE (Paraburkholderia xenovorans)	PF12697 (Abhydrolase_6)	5	LEU A 283 GLY A 63 ALA A 62 VAL A 279 ILE A 280	None	0.92A	2f81B-2ri6A: undetectable	2f81B-2ri6A: 15.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rkf	PROTEASE RETROPEPSIN (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None AB1 A 501 (-2.4A) AB1 A 501 (-3.9A) AB1 A 501 (-3.5A) AB1 A 501 ( 3.3A) AB1 A 501 (-3.8A) AB1 A 501 (-3.5A) AB1 A 501 (-3.8A) AB1 A 501 (-4.2A) AB1 A 501 ( 4.2A)	0.41A	2f81B-2rkfA: 20.6	2f81B-2rkfA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2rsp	RSV PROTEASE (Rous sarcoma virus)	PF00077 (RVP)	6	LEU A 35 ASP A 37 GLY A 39 ALA A 40 ASP A 41 ILE A 108	None	0.44A	2f81B-2rspA: 12.6	2f81B-2rspA: 32.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2wsk	GLYCOGEN DEBRANCHING ENZYME (Escherichia coli)	PF00128 (Alpha-amylase) PF02922 (CBM_48)	5	LEU A 188 GLY A 255 ALA A 254 ILE A 248 ILE A 185	None	0.81A	2f81B-2wskA: undetectable	2f81B-2wskA: 8.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ynm	LIGHT-INDEPENDENT PROTOCHLOROPHYLLIDE REDUCTASE IRON-SULFUR ATP-BINDING PROTEIN LIGHT-INDEPENDENT PROTOCHLOROPHYLLIDE REDUCTASE SUBUNIT N (Prochlorococcus marinus)	PF00142 (Fer4_NifH) PF00148 (Oxidored_nitro)	5	LEU A 87 ALA C 71 GLY A 126 VAL A 83 ILE A 84	None None SF4 A1302 (-3.9A) None EPE A1298 (-4.9A)	0.99A	2f81B-2ynmA: undetectable	2f81B-2ynmA: 17.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2zj8	PUTATIVE SKI2-TYPE HELICASE (Pyrococcus furiosus)	PF00270 (DEAD) PF00271 (Helicase_C) PF14520 (HHH_5)	5	LEU A 681 ALA A 661 GLY A 655 VAL A 692 ILE A 687	None	0.94A	2f81B-2zj8A: undetectable	2f81B-2zj8A: 9.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3aqp	PROBABLE SECDF PROTEIN-EXPORT MEMBRANE PROTEIN (Thermus thermophilus)	PF02355 (SecD_SecF) PF07549 (Sec_GG)	5	GLY A 327 ALA A 329 GLY A 274 ILE A 271 VAL A 693	None	0.89A	2f81B-3aqpA: undetectable	2f81B-3aqpA: 10.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3c4n	UNCHARACTERIZED PROTEIN DR_0571 (Deinococcus radiodurans)	PF01266 (DAO)	5	LEU A 370 GLY A 200 VAL A 40 VAL A 230 ILE A 228	None	0.87A	2f81B-3c4nA: undetectable	2f81B-3c4nA: 12.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3d43	SPHERICASE (Lysinibacillus sphaericus)	PF00082 (Peptidase_S8)	5	ALA A 97 ASP A 96 GLY A 92 PRO A 254 ILE A 30	None	0.93A	2f81B-3d43A: undetectable	2f81B-3d43A: 16.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3dbg	PUTATIVE CYTOCHROME P450 (Streptomyces coelicolor)	PF00067 (p450)	5	GLY A 359 ALA A 360 ASP A 361 PRO A 24 ILE A 356	None	0.87A	2f81B-3dbgA: undetectable	2f81B-3dbgA: 11.56
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3gve	YFKN PROTEIN (Bacillus subtilis)	PF00149 (Metallophos)	5	GLY A 121 ALA A 122 ASP A 123 ILE A 89 ILE A 126	None	0.64A	2f81B-3gveA: undetectable	2f81B-3gveA: 14.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hdy	UDP-GALACTOPYRANOSE MUTASE (Deinococcus radiodurans)	PF03275 (GLF) PF13450 (NAD_binding_8)	5	GLY A 38 ALA A 37 VAL A 237 VAL A 55 ILE A 57	FAD A 450 (-3.3A) None None None None	0.87A	2f81B-3hdyA: undetectable	2f81B-3hdyA: 13.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3hdy	UDP-GALACTOPYRANOSE MUTASE (Deinococcus radiodurans)	PF03275 (GLF) PF13450 (NAD_binding_8)	5	LEU A 230 ALA A 49 ILE A 256 VAL A 237 ILE A 235	None	0.91A	2f81B-3hdyA: undetectable	2f81B-3hdyA: 13.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3kyh	MRNA-CAPPING ENZYME SUBUNIT BETA (Saccharomyces cerevisiae)	PF02940 (mRNA_triPase)	5	ALA A 337 ASP A 336 ASP A 315 VAL A 322 ILE A 313	None	0.94A	2f81B-3kyhA: undetectable	2f81B-3kyhA: 15.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3lun	ULILYSIN (Methanosarcina acetivorans)	PF05572 (Peptidase_M43)	5	ALA A 209 ASP A 207 VAL A 175 ILE A 93 ILE A 205	None	0.97A	2f81B-3lunA: undetectable	2f81B-3lunA: 16.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdo	PUTATIVE PHOSPHORIBOSYLFORMYL GLYCINAMIDINE CYCLO-LIGASE (Parabacteroides distasonis)	PF02769 (AIRS_C)	5	LEU A 251 ALA A 255 ASP A 246 ILE A 319 ILE A 248	None	0.97A	2f81B-3mdoA: undetectable	2f81B-3mdoA: 14.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mdo	PUTATIVE PHOSPHORIBOSYLFORMYL GLYCINAMIDINE CYCLO-LIGASE (Parabacteroides distasonis)	PF02769 (AIRS_C)	5	LEU A 251 GLY A 256 ALA A 255 ILE A 319 ILE A 248	None	0.96A	2f81B-3mdoA: undetectable	2f81B-3mdoA: 14.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mmp	ELONGATION FACTOR TU 2, ELONGATION FACTOR TS (Escherichia coli)	PF00009 (GTP_EFTU) PF00889 (EF_TS) PF03143 (GTP_EFTU_D3) PF03144 (GTP_EFTU_D2)	5	GLY A 16 ALA A 17 ASP A 21 GLY A 126 ILE A 125	None	0.97A	2f81B-3mmpA: undetectable	2f81B-3mmpA: 10.02
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3mq0	TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON (Agrobacterium tumefaciens)	PF01614 (IclR) PF09339 (HTH_IclR)	5	LEU A 240 GLY A 254 VAL A 121 PRO A 118 ILE A 238	None	0.96A	2f81B-3mq0A: undetectable	2f81B-3mq0A: 15.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.75A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.53A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.37A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nek	NITROGEN REPRESSOR-LIKE PROTEIN MJ0159 (Methanocaldococcus jannaschii)	PF01995 (DUF128)	5	GLY A 457 ALA A 456 GLY A 480 ILE A 376 PRO A 511	GOL A 1 ( 4.7A) None None None None	0.93A	2f81B-3nekA: undetectable	2f81B-3nekA: 16.38
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3o8l	6-PHOSPHOFRUCTOKINAS E, MUSCLE TYPE (Oryctolagus cuniculus)	PF00365 (PFK)	5	GLY A 224 ALA A 225 ILE A 192 VAL A 207 ILE A 261	PO4 A 767 ( 4.6A) None None None None	0.96A	2f81B-3o8lA: undetectable	2f81B-3o8lA: 9.27
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3p4g	ANTIFREEZE PROTEIN (Marinomonas primoryensis)	no annotation	5	ASP A 103 GLY A 99 ALA A 98 VAL A 124 GLY A 137	CA A 403 ( 2.4A) CA A 403 (-4.1A) CA A 404 (-4.5A) None CA A 405 (-4.1A)	0.98A	2f81B-3p4gA: undetectable	2f81B-3p4gA: 13.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	5	ASP A 32 GLY A 34 ALA A 35 VAL A 39 PRO A 89	3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-4.0A)	0.58A	2f81B-3slzA: 11.3	2f81B-3slzA: 25.19
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3slz	GAG-PRO-POL POLYPROTEIN (Murine leukemia virus)	PF00077 (RVP)	6	LEU A 30 ASP A 32 GLY A 34 ALA A 35 VAL A 39 GLY A 56	None 3TL A 126 (-2.4A) 3TL A 126 (-3.1A) 3TL A 126 ( 4.0A) None 3TL A 126 (-3.4A)	0.41A	2f81B-3slzA: 11.3	2f81B-3slzA: 25.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3t3c	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	SO4 A 101 (-4.2A) 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.5A) 017 A 201 (-3.5A) 017 A 201 (-4.2A) None 017 A 201 (-4.0A) 017 A 201 (-3.3A) None	0.58A	2f81B-3t3cA: 18.3	2f81B-3t3cA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None 017 A 201 (-2.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-3.0A) 017 A 201 (-3.3A)	1.23A	2f81B-3ttpA: 19.4	2f81B-3ttpA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ttp	HIV-1 PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None 017 A 201 (-2.6A) 017 A 201 (-3.6A) 017 A 201 (-3.4A) 017 A 201 (-3.3A) 017 A 201 (-4.6A) 017 A 201 (-3.0A) 017 A 201 (-3.3A) 017 A 201 (-4.1A) 017 A 201 (-4.7A)	0.40A	2f81B-3ttpA: 19.4	2f81B-3ttpA: 75.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3u3i	NUCLEOCAPSID PROTEIN (Crimean-Congo hemorrhagic fever orthonairovirus)	PF02477 (Nairo_nucleo)	5	GLY A 340 ASP A 60 GLY A 383 ILE A 385 VAL A 68	None	0.94A	2f81B-3u3iA: undetectable	2f81B-3u3iA: 13.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50	None 017 A 202 ( 2.5A) 017 A 201 (-3.4A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A)	1.23A	2f81B-3u7sA: 19.7	2f81B-3u7sA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3u7s	POL POLYPROTEIN (Human immunodeficiency virus 1)	PF00077 (RVP)	9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None 017 A 202 ( 2.5A) 017 A 201 ( 3.5A) 017 A 201 (-3.4A) 017 A 201 (-3.2A) 017 A 201 ( 4.0A) 017 A 202 (-2.9A) 017 A 201 ( 3.5A) 017 A 202 (-4.0A)	0.35A	2f81B-3u7sA: 19.7	2f81B-3u7sA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3uhl	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 PRO A 81 VAL A 82	None	0.38A	2f81B-3uhlA: 16.0	2f81B-3uhlA: 81.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4c30	DNA HELICASE II (Deinococcus radiodurans)	PF00580 (UvrD-helicase) PF13361 (UvrD_C)	5	ALA A 180 GLY A 130 ILE A 135 VAL A 143 ILE A 144	None	0.95A	2f81B-4c30A: undetectable	2f81B-4c30A: 9.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4g6c	BETA-HEXOSAMINIDASE 1 (Burkholderia cenocepacia)	PF00933 (Glyco_hydro_3)	5	ASP A 128 GLY A 174 VAL A 136 ILE A 215 ILE A 137	None	0.91A	2f81B-4g6cA: undetectable	2f81B-4g6cA: 15.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ida	RIPENING-INDUCED PROTEIN (Fragaria vesca)	PF08240 (ADH_N) PF13602 (ADH_zinc_N_2)	5	LEU A 203 GLY A 208 ALA A 209 ASP A 210 ILE A 179	None	0.80A	2f81B-4idaA: undetectable	2f81B-4idaA: 17.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4inj	LMO1638 PROTEIN (Listeria monocytogenes)	PF02016 (Peptidase_S66)	5	LEU A 162 ALA A 309 GLY A 306 ILE A 305 ILE A 321	None	0.85A	2f81B-4injA: undetectable	2f81B-4injA: 15.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jlw	GLUTATHIONE-INDEPEND ENT FORMALDEHYDE DEHYDROGENASE (Pseudomonas aeruginosa)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	6	GLY A 175 ALA A 202 VAL A 190 GLY A 298 ILE A 299 ILE A 192	None	1.39A	2f81B-4jlwA: undetectable	2f81B-4jlwA: 12.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4m2j	AMINOTRANSFERASE (Streptomyces lavendulae)	PF00155 (Aminotran_1_2)	5	GLY A 278 ALA A 281 VAL A 311 GLY A 228 ILE A 200	None	0.96A	2f81B-4m2jA: undetectable	2f81B-4m2jA: 13.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4na3	POLYKETIDE SYNTHASE PKSJ (Bacillus subtilis)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C) PF16197 (KAsynt_C_assoc)	5	LEU A 180 GLY A 201 ALA A 200 ILE A 12 ILE A 183	None	0.94A	2f81B-4na3A: undetectable	2f81B-4na3A: 11.13
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	ALA A 28 ASP A 29 ASP A 30 GLY A 48 ILE A 84	RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) RIT A 500 (-4.8A) RIT A 500 (-4.3A)	0.71A	2f81B-4njvA: 20.2	2f81B-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	8	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) RIT A 500 (-4.8A) None RIT A 500 (-4.3A)	0.49A	2f81B-4njvA: 20.2	2f81B-4njvA: 85.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4njv	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None RIT A 500 (-2.4A) RIT A 500 (-3.9A) RIT A 500 (-3.6A) RIT A 500 (-3.2A) None RIT A 500 (-3.4A) RIT A 500 (-4.3A) RIT A 500 (-3.9A) RIT A 500 (-4.3A)	0.41A	2f81B-4njvA: 20.2	2f81B-4njvA: 85.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oh1	L-IDITOL 2-DEHYDROGENASE ([Clostridium] scindens)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	GLY A 247 ASP A 204 VAL A 202 GLY A 183 ILE A 178	None	0.91A	2f81B-4oh1A: undetectable	2f81B-4oh1A: 13.99
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4r01	PUTATIVE NADH-FLAVIN REDUCTASE (Streptococcus pneumoniae)	PF13460 (NAD_binding_10)	5	LEU A 190 GLY A 13 ALA A 12 GLY A 66 VAL A 148	None	0.80A	2f81B-4r01A: undetectable	2f81B-4r01A: 17.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4rzk	SMALL HEAT SHOCK PROTEIN HSP20 FAMILY (Sulfolobus solfataricus)	PF00011 (HSP20)	5	LEU A 121 ALA A 87 ILE A 90 PRO A 139 ILE A 136	None	0.87A	2f81B-4rzkA: undetectable	2f81B-4rzkA: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4tnb	G PROTEIN-COUPLED RECEPTOR KINASE 5 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	5	LEU A 45 ASP A 52 GLY A 63 ILE A 62 ILE A 49	None	0.97A	2f81B-4tnbA: undetectable	2f81B-4tnbA: 12.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydf	HTLV-1 PROTEASE (Primate T-lymphotropic virus 1)	PF00077 (RVP)	8	LEU A 30 ASP A 32 GLY A 34 ALA A 35 ASP A 36 VAL A 39 GLY A 58 ILE A 100	None 4B1 A 201 (-2.9A) 4B1 A 201 ( 4.6A) 4B1 A 201 (-3.6A) 4B1 A 201 (-4.4A) None 4B1 A 201 (-3.4A) 4B1 A 201 (-4.8A)	0.55A	2f81B-4ydfA: 12.6	2f81B-4ydfA: 31.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.51A	2f81B-5b18A: 17.9	2f81B-5b18A: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b18	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	5	GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 84	None	0.82A	2f81B-5b18A: 17.9	2f81B-5b18A: 74.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5erb	POLYKETIDE SYNTHASE (Bacillus amyloliquefaciens)	PF00109 (ketoacyl-synt) PF02801 (Ketoacyl-synt_C) PF16197 (KAsynt_C_assoc)	5	LEU A 187 GLY A 208 ALA A 207 ILE A 14 ILE A 190	None	0.99A	2f81B-5erbA: undetectable	2f81B-5erbA: 10.85
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5h1k	GEM-ASSOCIATED PROTEIN 5 (Homo sapiens)	PF00400 (WD40) PF12894 (ANAPC4_WD40)	5	LEU A 157 GLY A 132 VAL A 177 VAL A 167 ILE A 169	None	0.91A	2f81B-5h1kA: undetectable	2f81B-5h1kA: 8.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5jxk	ASP/GLU-SPECIFIC DIPEPTIDYL-PEPTIDASE (Porphyromonas endodontalis)	PF10459 (Peptidase_S46)	5	GLY A 583 ALA A 594 VAL A 263 ILE A 689 ILE A 581	None	0.96A	2f81B-5jxkA: undetectable	2f81B-5jxkA: 8.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5kzn	METABOTROPIC GLUTAMATE RECEPTOR 2 (Homo sapiens)	PF01094 (ANF_receptor) PF07562 (NCD3G)	5	LEU A 79 GLY A 85 ASP A 70 ILE A 140 ILE A 72	None	0.93A	2f81B-5kznA: undetectable	2f81B-5kznA: 11.59
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.24A	2f81B-5t2zA: 20.2	2f81B-5t2zA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5t2z	PROTEASE (Human immunodeficiency virus 1)	PF00077 (RVP)	11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.36A	2f81B-5t2zA: 20.2	2f81B-5t2zA: 81.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u2w	SHORT CHAIN DEHYDROGENASE (Burkholderia cenocepacia)	PF00106 (adh_short)	5	ALA A 170 ASP A 172 GLY A 164 ILE A 163 VAL A 137	None	0.95A	2f81B-5u2wA: undetectable	2f81B-5u2wA: 16.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ufm	METHYLTRANSFERASE DOMAIN PROTEIN (Burkholderia thailandensis)	no annotation	5	ASP A 95 GLY A 76 ASP A 72 VAL A 120 GLY A 136	SAH A 301 (-2.7A) SAH A 301 (-3.6A) None SAH A 301 (-4.1A) AZ8 A 302 ( 3.5A)	0.81A	2f81B-5ufmA: undetectable	2f81B-5ufmA: 20.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ve3	BPPRF (Paraburkholderia phytofirmans)	no annotation	5	GLY B 88 ALA B 89 ASP B 90 VAL B 59 ILE B 80	None	0.93A	2f81B-5ve3B: undetectable	2f81B-5ve3B: 13.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vm2	ALCOHOL DEHYDROGENASE (Escherichia coli)	PF00107 (ADH_zinc_N) PF08240 (ADH_N)	5	GLY A 237 ALA A 238 ASP A 239 VAL A 199 ILE A 173	None	0.80A	2f81B-5vm2A: undetectable	2f81B-5vm2A: 16.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5xj1	UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029 (Streptococcus pneumoniae)	no annotation	5	GLY A 399 ALA A 400 ASP A 401 ILE A 373 ILE A 378	None	0.92A	2f81B-5xj1A: undetectable	2f81B-5xj1A: 15.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fiv	RETROPEPSIN (Feline immunodeficiency virus)	PF00077 (RVP)	7	LEU A 28 ASP A 30 GLY A 32 ALA A 33 ASP A 34 GLY A 58 VAL A 99	None 3TL A 201 (-3.5A) 3TL A 201 (-3.4A) 3TL A 201 (-4.0A) 3TL A 201 (-3.9A) 3TL A 201 (-3.4A) None	0.38A	2f81B-6fivA: 15.6	2f81B-6fivA: 31.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-3.6A) None None NIU A 100 ( 3.8A) None	0.65A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 PRO A 81	None NIU A 100 (-2.8A) NIU A 100 (-3.6A) None NIU A 100 ( 3.8A) None	0.70A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 ASP A 29 ASP A 30 GLY A 49 ILE A 50 ILE A 84	None NIU A 100 (-2.8A) None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.77A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	6	LEU A 23 ASP A 25 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None NIU A 100 (-2.8A) None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.83A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) NIU A 100 (-3.6A) None None None	0.56A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	7	LEU A 23 ASP A 25 GLY A 27 ASP A 29 ASP A 30 ILE A 50 ILE A 84	None NIU A 100 (-2.8A) NIU A 100 (-4.5A) None None NIU A 100 (-3.9A) None	0.58A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6upj	HIV-2 PROTEASE (Human immunodeficiency virus 2)	PF00077 (RVP)	5	LEU A 23 ASP A 30 GLY A 49 ILE A 50 PRO A 81	None None NIU A 100 ( 3.8A) NIU A 100 (-3.9A) None	0.98A	2f81B-6upjA: 17.5	2f81B-6upjA: 48.48

[["2F81_A_017A302_2","1czi","Bos taurus","CHYMOSIN","PF00026(Asp)",5,"ASP E 215;GLY E 217;VAL E 222;GLY E  76;ILE E 300","None","0.75A","2f81B-1cziE:6.7","2f81B-1cziE:17.42"],["2F81_A_017A302_2","1czi","Bos taurus","CHYMOSIN","PF00026(Asp)",5,"LEU E  30;ASP E  32;GLY E  34;ASP E  37;ILE E 120","None","0.59A","2f81B-1cziE:6.7","2f81B-1cziE:17.42"],["2F81_A_017A302_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;GLY A  48;VAL A  82;ILE A  84","A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 (-4.1A);A79 A 800 (-4.5A);A79 A 800 (-3.8A)","0.66A","2f81B-1hvcA:14.0","2f81B-1hvcA:46.31"],["2F81_A_017A302_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.1A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.9A);A79 A 800 (-4.5A);A79 A 800 (-3.6A)","0.62A","2f81B-1hvcA:14.0","2f81B-1hvcA:46.31"],["2F81_A_017A302_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","A79 A 800 ( 4.0A);A79 A 800 (-2.8A);A79 A 800 (-3.0A);A79 A 800 (-3.2A);A79 A 800 (-2.7A);A79 A 800 ( 4.7A);A79 A 800 ( 4.3A);A79 A 800 (-3.4A);A79 A 800 ( 4.0A);A79 A 800 ( 3.4A);A79 A 800 (-4.5A);A79 A 800 (-3.8A)","0.44A","2f81B-1hvcA:14.0","2f81B-1hvcA:46.31"],["2F81_A_017A302_2","1hvc","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","A79 A 800 ( 3.8A);A79 A 800 (-2.7A);A79 A 800 (-3.0A);A79 A 800 (-3.1A);A79 A 800 (-2.8A);A79 A 800 ( 4.9A);A79 A 800 ( 4.4A);A79 A 800 ( 3.7A);A79 A 800 (-3.8A);A79 A 800 (-4.5A);A79 A 800 (-3.6A)","0.42A","2f81B-1hvcA:14.0","2f81B-1hvcA:46.31"],["2F81_A_017A302_2","1hyl","Hypoderma lineatum","HYPODERMA LINEATUM COLLAGENASE","PF00089(Trypsin)",5,"LEU A 209;ALA A 136;GLY A 183;VAL A 231;ILE A 210","None","0.93A","2f81B-1hylA:undetectable","2f81B-1hylA:20.35"],["2F81_A_017A302_2","1j2b","Pyrococcus horikoshii","ARCHAEOSINE TRNA-GUANINE TRANSGLYCOSYLASE","PF01472(PUA);PF01702(TGT);PF14809(TGT_C1);PF14810(TGT_C2)",5,"ASP A 535;GLY A 537;ASP A 542;GLY A 449;PRO A 504","None","0.78A","2f81B-1j2bA:undetectable","2f81B-1j2bA:11.01"],["2F81_A_017A302_2","1kae","Escherichia coli","HISTIDINOL DEHYDROGENASE","PF00815(Histidinol_dh)",5,"GLY A 227;ALA A 228;ASP A 204;GLY A 196;ILE A 206","None","0.82A","2f81B-1kaeA:undetectable","2f81B-1kaeA:13.46"],["2F81_A_017A302_2","1l3i","Methanothermobacter thermautotrophicus","PRECORRIN-6Y METHYLTRANSFERASE\/PUTATIVE DECARBOXYLASE","PF13847(Methyltransf_31)",5,"LEU A 136;GLY A 108;VAL A 179;GLY A  15;ILE A 135","None;SAH A 801 (-3.4A);None;SAH A 801 ( 3.8A);None","0.89A","2f81B-1l3iA:undetectable","2f81B-1l3iA:20.62"],["2F81_A_017A302_2","1lk5","Pyrococcus horikoshii","D-RIBOSE-5-PHOSPHATE ISOMERASE","PF06026(Rib_5-P_isom_A)",5,"GLY A 101;ALA A 102;GLY A 207;ILE A  97;ILE A 179"," CL A1001 (-3.4A);None;None;None;None","0.98A","2f81B-1lk5A:undetectable","2f81B-1lk5A:20.52"],["2F81_A_017A302_2","1prs","Myxococcus xanthus","DEVELOPMENT-SPECIFIC PROTEIN S","PF00030(Crystall)",5,"LEU A  19;GLY A  22;VAL A  44;VAL A   6;ILE A   4","None","0.92A","2f81B-1prsA:undetectable","2f81B-1prsA:23.39"],["2F81_A_017A302_2","1q9p","Homo sapiens","HIV-1 PROTEASE","PF00077(RVP)",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.56A","2f81B-1q9pA:10.0","2f81B-1q9pA:98.95"],["2F81_A_017A302_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.20A","2f81B-1sivA:18.5","2f81B-1sivA:50.98"],["2F81_A_017A302_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","None","0.37A","2f81B-1sivA:18.5","2f81B-1sivA:50.98"],["2F81_A_017A302_2","1siv","Simian immunodeficiency virus","SIV PROTEASE","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;ILE A  84","None","0.38A","2f81B-1sivA:18.5","2f81B-1sivA:50.98"],["2F81_A_017A302_2","1tjr","Zea mays","BX1","PF00290(Trp_syntA)",5,"GLY A 307;ALA A 308;ASP A 309;VAL A 269;ILE A 303","None","0.84A","2f81B-1tjrA:undetectable","2f81B-1tjrA:19.59"],["2F81_A_017A302_2","1to6","Neisseria meningitidis","GLYCERATE KINASE","PF02595(Gly_kinase)",5,"ALA A 190;ASP A 191;GLY A 244;ILE A 247;ILE A 259","None;None;SO4 A 373 (-3.5A);None;None","0.81A","2f81B-1to6A:undetectable","2f81B-1to6A:15.76"],["2F81_A_017A302_2","1u2e","Escherichia coli","2-HYDROXY-6-KETONONA-2,4-DIENEDIOIC ACID HYDROLASE","PF12697(Abhydrolase_6)",5,"LEU A 281;GLY A  61;ALA A  60;ILE A  54;VAL A 277","None","0.96A","2f81B-1u2eA:undetectable","2f81B-1u2eA:20.00"],["2F81_A_017A302_2","1uww","Bacillus akibai","ENDOGLUCANASE","PF03424(CBM_17_28)",5,"ALA A 122;VAL A  89;ILE A 169;VAL A 147;ILE A 149","None","0.96A","2f81B-1uwwA:undetectable","2f81B-1uwwA:21.13"],["2F81_A_017A302_2","1v5f","Aerococcus viridans","PYRUVATE OXIDASE","PF00205(TPP_enzyme_M);PF02775(TPP_enzyme_C);PF02776(TPP_enzyme_N)",5,"ASP A 388;ALA A 444;ASP A 442;VAL A 466;ILE A 440","None;TPP A1602 (-3.7A); MG A1603 ( 2.8A);None;None","0.97A","2f81B-1v5fA:undetectable","2f81B-1v5fA:10.80"],["2F81_A_017A302_2","1wsv","Homo sapiens","AMINOMETHYLTRANSFERASE","PF01571(GCV_T);PF08669(GCV_T_C)",5,"LEU A 152;VAL A 192;GLY A 166;VAL A 207;ILE A 205","LEU A 152 ( 0.6A);VAL A 192 ( 0.6A);GLY A 166 ( 0.0A);VAL A 207 ( 0.6A);ILE A 205 ( 0.4A)","0.88A","2f81B-1wsvA:undetectable","2f81B-1wsvA:14.67"],["2F81_A_017A302_2","1yg0","Helicobacter pylori","COP ASSOCIATED PROTEIN","PF00403(HMA)",5,"GLY A  62;ALA A  61;ASP A  60;VAL A  23;ILE A  19","None","0.96A","2f81B-1yg0A:undetectable","2f81B-1yg0A:19.00"],["2F81_A_017A302_2","2cvj","Thermus thermophilus","THIOREDOXIN REDUCTASE RELATED PROTEIN","PF00890(FAD_binding_2);PF07992(Pyr_redox_2)",5,"LEU A 170;GLY A  24;ALA A  23;ASP A 177;VAL A 164","None","0.99A","2f81B-2cvjA:undetectable","2f81B-2cvjA:16.02"],["2F81_A_017A302_2","2dph","Pseudomonas putida","FORMALDEHYDE DISMUTASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",6,"GLY A 174;ALA A 201;VAL A 189;GLY A 296;ILE A 297;ILE A 191","None","1.43A","2f81B-2dphA:undetectable","2f81B-2dphA:14.51"],["2F81_A_017A302_2","2e4u","Rattus norvegicus","METABOTROPIC GLUTAMATE RECEPTOR 3","PF01094(ANF_receptor);PF07562(NCD3G)",5,"LEU A  86;GLY A  92;ASP A  77;ILE A 146;ILE A  79","None","0.90A","2f81B-2e4uA:undetectable","2f81B-2e4uA:11.54"],["2F81_A_017A302_2","2ewn","Escherichia coli","BIRA BIFUNCTIONAL PROTEIN","PF02237(BPL_C);PF03099(BPL_LplA_LipB);PF08279(HTH_11)",5,"GLY A 186;ALA A 185;GLY A 154;ILE A 153;ILE A 207","BTX A 501 (-3.3A);None;None;None;None","0.74A","2f81B-2ewnA:undetectable","2f81B-2ewnA:17.95"],["2F81_A_017A302_2","2fmb","Equine infectious anemia virus","EQUINE INFECTIOUS ANEMIA VIRUS PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  55;PRO A  86;VAL A  87;ILE A  89","None;LP1 A 201 (-2.3A);LP1 A 201 (-3.8A);LP1 A 201 (-3.5A);LP1 A 201 (-3.6A);None;LP1 A 201 (-3.4A);LP1 A 201 (-3.9A);LP1 A 201 ( 4.9A);LP1 A 201 (-4.2A)","0.39A","2f81B-2fmbA:15.0","2f81B-2fmbA:33.02"],["2F81_A_017A302_2","2g28","Escherichia coli","PYRUVATE DEHYDROGENASE E1 COMPONENT","PF00456(Transketolase_N)",5,"LEU A 565;GLY A 573;PRO A 594;VAL A 516;ILE A 518","None","0.84A","2f81B-2g28A:undetectable","2f81B-2g28A:8.09"],["2F81_A_017A302_2","2ri6","Paraburkholderia xenovorans","2-HYDROXY-6-OXO-6-PHENYLHEXA-2,4-DIENOATE HYDROLASE","PF12697(Abhydrolase_6)",5,"LEU A 283;GLY A  63;ALA A  62;VAL A 279;ILE A 280","None","0.92A","2f81B-2ri6A:undetectable","2f81B-2ri6A:15.66"],["2F81_A_017A302_2","2rkf","Human immunodeficiency virus 1","PROTEASE RETROPEPSIN","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;AB1 A 501 (-2.4A);AB1 A 501 (-3.9A);AB1 A 501 (-3.5A);AB1 A 501 ( 3.3A);AB1 A 501 (-3.8A);AB1 A 501 (-3.5A);AB1 A 501 (-3.8A);AB1 A 501 (-4.2A);AB1 A 501 ( 4.2A)","0.41A","2f81B-2rkfA:20.6","2f81B-2rkfA:81.82"],["2F81_A_017A302_2","2rsp","Rous sarcoma virus","RSV PROTEASE","PF00077(RVP)",6,"LEU A  35;ASP A  37;GLY A  39;ALA A  40;ASP A  41;ILE A 108","None","0.44A","2f81B-2rspA:12.6","2f81B-2rspA:32.80"],["2F81_A_017A302_2","2wsk","Escherichia coli","GLYCOGEN DEBRANCHING ENZYME","PF00128(Alpha-amylase);PF02922(CBM_48)",5,"LEU A 188;GLY A 255;ALA A 254;ILE A 248;ILE A 185","None","0.81A","2f81B-2wskA:undetectable","2f81B-2wskA:8.70"],["2F81_A_017A302_2","2ynm","Prochlorococcus marinus","LIGHT-INDEPENDENT PROTOCHLOROPHYLLIDE REDUCTASE IRON-SULFUR ATP-BINDING PROTEIN;LIGHT-INDEPENDENT PROTOCHLOROPHYLLIDE REDUCTASE SUBUNIT N","PF00142(Fer4_NifH);PF00148(Oxidored_nitro)",5,"LEU A  87;ALA C  71;GLY A 126;VAL A  83;ILE A  84","None;None;SF4 A1302 (-3.9A);None;EPE A1298 (-4.9A)","0.99A","2f81B-2ynmA:undetectable","2f81B-2ynmA:17.73"],["2F81_A_017A302_2","2zj8","Pyrococcus furiosus","PUTATIVE SKI2-TYPE HELICASE","PF00270(DEAD);PF00271(Helicase_C);PF14520(HHH_5)",5,"LEU A 681;ALA A 661;GLY A 655;VAL A 692;ILE A 687","None","0.94A","2f81B-2zj8A:undetectable","2f81B-2zj8A:9.41"],["2F81_A_017A302_2","3aqp","Thermus thermophilus","PROBABLE SECDF PROTEIN-EXPORT MEMBRANE PROTEIN","PF02355(SecD_SecF);PF07549(Sec_GG)",5,"GLY A 327;ALA A 329;GLY A 274;ILE A 271;VAL A 693","None","0.89A","2f81B-3aqpA:undetectable","2f81B-3aqpA:10.10"],["2F81_A_017A302_2","3c4n","Deinococcus radiodurans","UNCHARACTERIZED PROTEIN DR_0571","PF01266(DAO)",5,"LEU A 370;GLY A 200;VAL A  40;VAL A 230;ILE A 228","None","0.87A","2f81B-3c4nA:undetectable","2f81B-3c4nA:12.15"],["2F81_A_017A302_2","3d43","Lysinibacillus sphaericus","SPHERICASE","PF00082(Peptidase_S8)",5,"ALA A  97;ASP A  96;GLY A  92;PRO A 254;ILE A  30","None","0.93A","2f81B-3d43A:undetectable","2f81B-3d43A:16.45"],["2F81_A_017A302_2","3dbg","Streptomyces coelicolor","PUTATIVE CYTOCHROME P450","PF00067(p450)",5,"GLY A 359;ALA A 360;ASP A 361;PRO A  24;ILE A 356","None","0.87A","2f81B-3dbgA:undetectable","2f81B-3dbgA:11.56"],["2F81_A_017A302_2","3gve","Bacillus subtilis","YFKN PROTEIN","PF00149(Metallophos)",5,"GLY A 121;ALA A 122;ASP A 123;ILE A  89;ILE A 126","None","0.64A","2f81B-3gveA:undetectable","2f81B-3gveA:14.41"],["2F81_A_017A302_2","3hdy","Deinococcus radiodurans","UDP-GALACTOPYRANOSE MUTASE","PF03275(GLF);PF13450(NAD_binding_8)",5,"GLY A  38;ALA A  37;VAL A 237;VAL A  55;ILE A  57","FAD A 450 (-3.3A);None;None;None;None","0.87A","2f81B-3hdyA:undetectable","2f81B-3hdyA:13.38"],["2F81_A_017A302_2","3hdy","Deinococcus radiodurans","UDP-GALACTOPYRANOSE MUTASE","PF03275(GLF);PF13450(NAD_binding_8)",5,"LEU A 230;ALA A  49;ILE A 256;VAL A 237;ILE A 235","None","0.91A","2f81B-3hdyA:undetectable","2f81B-3hdyA:13.38"],["2F81_A_017A302_2","3kyh","Saccharomyces cerevisiae","MRNA-CAPPING ENZYME SUBUNIT BETA","PF02940(mRNA_triPase)",5,"ALA A 337;ASP A 336;ASP A 315;VAL A 322;ILE A 313","None","0.94A","2f81B-3kyhA:undetectable","2f81B-3kyhA:15.61"],["2F81_A_017A302_2","3lun","Methanosarcina acetivorans","ULILYSIN","PF05572(Peptidase_M43)",5,"ALA A 209;ASP A 207;VAL A 175;ILE A  93;ILE A 205","None","0.97A","2f81B-3lunA:undetectable","2f81B-3lunA:16.60"],["2F81_A_017A302_2","3mdo","Parabacteroides distasonis","PUTATIVE PHOSPHORIBOSYLFORMYLGLYCINAMIDINE CYCLO-LIGASE","PF02769(AIRS_C)",5,"LEU A 251;ALA A 255;ASP A 246;ILE A 319;ILE A 248","None","0.97A","2f81B-3mdoA:undetectable","2f81B-3mdoA:14.14"],["2F81_A_017A302_2","3mdo","Parabacteroides distasonis","PUTATIVE PHOSPHORIBOSYLFORMYLGLYCINAMIDINE CYCLO-LIGASE","PF02769(AIRS_C)",5,"LEU A 251;GLY A 256;ALA A 255;ILE A 319;ILE A 248","None","0.96A","2f81B-3mdoA:undetectable","2f81B-3mdoA:14.14"],["2F81_A_017A302_2","3mmp","Escherichia coli","ELONGATION FACTOR TU 2, ELONGATION FACTOR TS","PF00009(GTP_EFTU);PF00889(EF_TS);PF03143(GTP_EFTU_D3);PF03144(GTP_EFTU_D2)",5,"GLY A  16;ALA A  17;ASP A  21;GLY A 126;ILE A 125","None","0.97A","2f81B-3mmpA:undetectable","2f81B-3mmpA:10.02"],["2F81_A_017A302_2","3mq0","Agrobacterium tumefaciens","TRANSCRIPTIONAL REPRESSOR OF THE BLCABC OPERON","PF01614(IclR);PF09339(HTH_IclR)",5,"LEU A 240;GLY A 254;VAL A 121;PRO A 118;ILE A 238","None","0.96A","2f81B-3mq0A:undetectable","2f81B-3mq0A:15.59"],["2F81_A_017A302_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.75A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.53A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","3mws","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.37A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","3nek","Methanocaldococcus jannaschii","NITROGEN REPRESSOR-LIKE PROTEIN MJ0159","PF01995(DUF128)",5,"GLY A 457;ALA A 456;GLY A 480;ILE A 376;PRO A 511","GOL A   1 ( 4.7A);None;None;None;None","0.93A","2f81B-3nekA:undetectable","2f81B-3nekA:16.38"],["2F81_A_017A302_2","3o8l","Oryctolagus cuniculus","6-PHOSPHOFRUCTOKINASE, MUSCLE TYPE","PF00365(PFK)",5,"GLY A 224;ALA A 225;ILE A 192;VAL A 207;ILE A 261","PO4 A 767 ( 4.6A);None;None;None;None","0.96A","2f81B-3o8lA:undetectable","2f81B-3o8lA:9.27"],["2F81_A_017A302_2","3p4g","Marinomonas primoryensis","ANTIFREEZE PROTEIN","no annotation",5,"ASP A 103;GLY A  99;ALA A  98;VAL A 124;GLY A 137"," CA A 403 ( 2.4A); CA A 403 (-4.1A); CA A 404 (-4.5A);None; CA A 405 (-4.1A)","0.98A","2f81B-3p4gA:undetectable","2f81B-3p4gA:13.85"],["2F81_A_017A302_2","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",5,"ASP A  32;GLY A  34;ALA A  35;VAL A  39;PRO A  89","3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-4.0A)","0.58A","2f81B-3slzA:11.3","2f81B-3slzA:25.19"],["2F81_A_017A302_2","3slz","Murine leukemia virus","GAG-PRO-POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;VAL A  39;GLY A  56","None;3TL A 126 (-2.4A);3TL A 126 (-3.1A);3TL A 126 ( 4.0A);None;3TL A 126 (-3.4A)","0.41A","2f81B-3slzA:11.3","2f81B-3slzA:25.19"],["2F81_A_017A302_2","3t3c","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","SO4 A 101 (-4.2A);017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.5A);017 A 201 (-3.5A);017 A 201 (-4.2A);None;017 A 201 (-4.0A);017 A 201 (-3.3A);None","0.58A","2f81B-3t3cA:18.3","2f81B-3t3cA:75.76"],["2F81_A_017A302_2","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None;017 A 201 (-2.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-3.0A);017 A 201 (-3.3A)","1.23A","2f81B-3ttpA:19.4","2f81B-3ttpA:75.76"],["2F81_A_017A302_2","3ttp","Human immunodeficiency virus 1","HIV-1 PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;017 A 201 (-2.6A);017 A 201 (-3.6A);017 A 201 (-3.4A);017 A 201 (-3.3A);017 A 201 (-4.6A);017 A 201 (-3.0A);017 A 201 (-3.3A);017 A 201 (-4.1A);017 A 201 (-4.7A)","0.40A","2f81B-3ttpA:19.4","2f81B-3ttpA:75.76"],["2F81_A_017A302_2","3u3i","Crimean-Congo hemorrhagic fever orthonairovirus","NUCLEOCAPSID PROTEIN","PF02477(Nairo_nucleo)",5,"GLY A 340;ASP A  60;GLY A 383;ILE A 385;VAL A  68","None","0.94A","2f81B-3u3iA:undetectable","2f81B-3u3iA:13.83"],["2F81_A_017A302_2","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50","None;017 A 202 ( 2.5A);017 A 201 (-3.4A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A)","1.23A","2f81B-3u7sA:19.7","2f81B-3u7sA:77.78"],["2F81_A_017A302_2","3u7s","Human immunodeficiency virus 1","POL POLYPROTEIN","PF00077(RVP)",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None;017 A 202 ( 2.5A);017 A 201 ( 3.5A);017 A 201 (-3.4A);017 A 201 (-3.2A);017 A 201 ( 4.0A);017 A 202 (-2.9A);017 A 201 ( 3.5A);017 A 202 (-4.0A)","0.35A","2f81B-3u7sA:19.7","2f81B-3u7sA:77.78"],["2F81_A_017A302_2","3uhl","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;PRO A  81;VAL A  82","None","0.38A","2f81B-3uhlA:16.0","2f81B-3uhlA:81.82"],["2F81_A_017A302_2","4c30","Deinococcus radiodurans","DNA HELICASE II","PF00580(UvrD-helicase);PF13361(UvrD_C)",5,"ALA A 180;GLY A 130;ILE A 135;VAL A 143;ILE A 144","None","0.95A","2f81B-4c30A:undetectable","2f81B-4c30A:9.89"],["2F81_A_017A302_2","4g6c","Burkholderia cenocepacia","BETA-HEXOSAMINIDASE 1","PF00933(Glyco_hydro_3)",5,"ASP A 128;GLY A 174;VAL A 136;ILE A 215;ILE A 137","None","0.91A","2f81B-4g6cA:undetectable","2f81B-4g6cA:15.18"],["2F81_A_017A302_2","4ida","Fragaria vesca","RIPENING-INDUCED PROTEIN","PF08240(ADH_N);PF13602(ADH_zinc_N_2)",5,"LEU A 203;GLY A 208;ALA A 209;ASP A 210;ILE A 179","None","0.80A","2f81B-4idaA:undetectable","2f81B-4idaA:17.76"],["2F81_A_017A302_2","4inj","Listeria monocytogenes","LMO1638 PROTEIN","PF02016(Peptidase_S66)",5,"LEU A 162;ALA A 309;GLY A 306;ILE A 305;ILE A 321","None","0.85A","2f81B-4injA:undetectable","2f81B-4injA:15.72"],["2F81_A_017A302_2","4jlw","Pseudomonas aeruginosa","GLUTATHIONE-INDEPENDENT FORMALDEHYDE DEHYDROGENASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",6,"GLY A 175;ALA A 202;VAL A 190;GLY A 298;ILE A 299;ILE A 192","None","1.39A","2f81B-4jlwA:undetectable","2f81B-4jlwA:12.73"],["2F81_A_017A302_2","4m2j","Streptomyces lavendulae","AMINOTRANSFERASE","PF00155(Aminotran_1_2)",5,"GLY A 278;ALA A 281;VAL A 311;GLY A 228;ILE A 200","None","0.96A","2f81B-4m2jA:undetectable","2f81B-4m2jA:13.11"],["2F81_A_017A302_2","4na3","Bacillus subtilis","POLYKETIDE SYNTHASE PKSJ","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C);PF16197(KAsynt_C_assoc)",5,"LEU A 180;GLY A 201;ALA A 200;ILE A  12;ILE A 183","None","0.94A","2f81B-4na3A:undetectable","2f81B-4na3A:11.13"],["2F81_A_017A302_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;ILE A  84","RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);RIT A 500 (-4.8A);RIT A 500 (-4.3A)","0.71A","2f81B-4njvA:20.2","2f81B-4njvA:85.86"],["2F81_A_017A302_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);RIT A 500 (-4.8A);None;RIT A 500 (-4.3A)","0.49A","2f81B-4njvA:20.2","2f81B-4njvA:85.86"],["2F81_A_017A302_2","4njv","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None;RIT A 500 (-2.4A);RIT A 500 (-3.9A);RIT A 500 (-3.6A);RIT A 500 (-3.2A);None;RIT A 500 (-3.4A);RIT A 500 (-4.3A);RIT A 500 (-3.9A);RIT A 500 (-4.3A)","0.41A","2f81B-4njvA:20.2","2f81B-4njvA:85.86"],["2F81_A_017A302_2","4oh1","[Clostridium] scindens","L-IDITOL 2-DEHYDROGENASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"GLY A 247;ASP A 204;VAL A 202;GLY A 183;ILE A 178","None","0.91A","2f81B-4oh1A:undetectable","2f81B-4oh1A:13.99"],["2F81_A_017A302_2","4r01","Streptococcus pneumoniae","PUTATIVE NADH-FLAVIN REDUCTASE","PF13460(NAD_binding_10)",5,"LEU A 190;GLY A  13;ALA A  12;GLY A  66;VAL A 148","None","0.80A","2f81B-4r01A:undetectable","2f81B-4r01A:17.13"],["2F81_A_017A302_2","4rzk","Sulfolobus solfataricus","SMALL HEAT SHOCK PROTEIN HSP20 FAMILY","PF00011(HSP20)",5,"LEU A 121;ALA A  87;ILE A  90;PRO A 139;ILE A 136","None","0.87A","2f81B-4rzkA:undetectable","2f81B-4rzkA:20.00"],["2F81_A_017A302_2","4tnb","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 5","PF00069(Pkinase);PF00615(RGS)",5,"LEU A  45;ASP A  52;GLY A  63;ILE A  62;ILE A  49","None","0.97A","2f81B-4tnbA:undetectable","2f81B-4tnbA:12.14"],["2F81_A_017A302_2","4ydf","Primate T-lymphotropic virus 1","HTLV-1 PROTEASE","PF00077(RVP)",8,"LEU A  30;ASP A  32;GLY A  34;ALA A  35;ASP A  36;VAL A  39;GLY A  58;ILE A 100","None;4B1 A 201 (-2.9A);4B1 A 201 ( 4.6A);4B1 A 201 (-3.6A);4B1 A 201 (-4.4A);None;4B1 A 201 (-3.4A);4B1 A 201 (-4.8A)","0.55A","2f81B-4ydfA:12.6","2f81B-4ydfA:31.30"],["2F81_A_017A302_2","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.51A","2f81B-5b18A:17.9","2f81B-5b18A:74.75"],["2F81_A_017A302_2","5b18","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",5,"GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  84","None","0.82A","2f81B-5b18A:17.9","2f81B-5b18A:74.75"],["2F81_A_017A302_2","5erb","Bacillus amyloliquefaciens","POLYKETIDE SYNTHASE","PF00109(ketoacyl-synt);PF02801(Ketoacyl-synt_C);PF16197(KAsynt_C_assoc)",5,"LEU A 187;GLY A 208;ALA A 207;ILE A  14;ILE A 190","None","0.99A","2f81B-5erbA:undetectable","2f81B-5erbA:10.85"],["2F81_A_017A302_2","5h1k","Homo sapiens","GEM-ASSOCIATED PROTEIN 5","PF00400(WD40);PF12894(ANAPC4_WD40)",5,"LEU A 157;GLY A 132;VAL A 177;VAL A 167;ILE A 169","None","0.91A","2f81B-5h1kA:undetectable","2f81B-5h1kA:8.75"],["2F81_A_017A302_2","5jxk","Porphyromonas endodontalis","ASP\/GLU-SPECIFIC DIPEPTIDYL-PEPTIDASE","PF10459(Peptidase_S46)",5,"GLY A 583;ALA A 594;VAL A 263;ILE A 689;ILE A 581","None","0.96A","2f81B-5jxkA:undetectable","2f81B-5jxkA:8.95"],["2F81_A_017A302_2","5kzn","Homo sapiens","METABOTROPIC GLUTAMATE RECEPTOR 2","PF01094(ANF_receptor);PF07562(NCD3G)",5,"LEU A  79;GLY A  85;ASP A  70;ILE A 140;ILE A  72","None","0.93A","2f81B-5kznA:undetectable","2f81B-5kznA:11.59"],["2F81_A_017A302_2","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.24A","2f81B-5t2zA:20.2","2f81B-5t2zA:81.82"],["2F81_A_017A302_2","5t2z","Human immunodeficiency virus 1","PROTEASE","PF00077(RVP)",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.36A","2f81B-5t2zA:20.2","2f81B-5t2zA:81.82"],["2F81_A_017A302_2","5u2w","Burkholderia cenocepacia","SHORT CHAIN DEHYDROGENASE","PF00106(adh_short)",5,"ALA A 170;ASP A 172;GLY A 164;ILE A 163;VAL A 137","None","0.95A","2f81B-5u2wA:undetectable","2f81B-5u2wA:16.41"],["2F81_A_017A302_2","5ufm","Burkholderia thailandensis","METHYLTRANSFERASE DOMAIN PROTEIN","no annotation",5,"ASP A  95;GLY A  76;ASP A  72;VAL A 120;GLY A 136","SAH A 301 (-2.7A);SAH A 301 (-3.6A);None;SAH A 301 (-4.1A);AZ8 A 302 ( 3.5A)","0.81A","2f81B-5ufmA:undetectable","2f81B-5ufmA:20.00"],["2F81_A_017A302_2","5ve3","Paraburkholderia phytofirmans","BPPRF","no annotation",5,"GLY B  88;ALA B  89;ASP B  90;VAL B  59;ILE B  80","None","0.93A","2f81B-5ve3B:undetectable","2f81B-5ve3B:13.41"],["2F81_A_017A302_2","5vm2","Escherichia coli","ALCOHOL DEHYDROGENASE","PF00107(ADH_zinc_N);PF08240(ADH_N)",5,"GLY A 237;ALA A 238;ASP A 239;VAL A 199;ILE A 173","None","0.80A","2f81B-5vm2A:undetectable","2f81B-5vm2A:16.55"],["2F81_A_017A302_2","5xj1","Streptococcus pneumoniae","UNCHARACTERIZED RNA METHYLTRANSFERASE SP_1029","no annotation",5,"GLY A 399;ALA A 400;ASP A 401;ILE A 373;ILE A 378","None","0.92A","2f81B-5xj1A:undetectable","2f81B-5xj1A:15.21"],["2F81_A_017A302_2","6fiv","Feline immunodeficiency virus","RETROPEPSIN","PF00077(RVP)",7,"LEU A  28;ASP A  30;GLY A  32;ALA A  33;ASP A  34;GLY A  58;VAL A  99","None;3TL A 201 (-3.5A);3TL A 201 (-3.4A);3TL A 201 (-4.0A);3TL A 201 (-3.9A);3TL A 201 (-3.4A);None","0.38A","2f81B-6fivA:15.6","2f81B-6fivA:31.40"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-3.6A);None;None;NIU A 100 ( 3.8A);None","0.65A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;PRO A  81","None;NIU A 100 (-2.8A);NIU A 100 (-3.6A);None;NIU A 100 ( 3.8A);None","0.70A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;ASP A  29;ASP A  30;GLY A  49;ILE A  50;ILE A  84","None;NIU A 100 (-2.8A);None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.77A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",6,"LEU A  23;ASP A  25;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None;NIU A 100 (-2.8A);None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.83A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);NIU A 100 (-3.6A);None;None;None","0.56A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",7,"LEU A  23;ASP A  25;GLY A  27;ASP A  29;ASP A  30;ILE A  50;ILE A  84","None;NIU A 100 (-2.8A);NIU A 100 (-4.5A);None;None;NIU A 100 (-3.9A);None","0.58A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"],["2F81_A_017A302_2","6upj","Human immunodeficiency virus 2","HIV-2 PROTEASE","PF00077(RVP)",5,"LEU A  23;ASP A  30;GLY A  49;ILE A  50;PRO A  81","None;None;NIU A 100 ( 3.8A);NIU A 100 (-3.9A);None","0.98A","2f81B-6upjA:17.5","2f81B-6upjA:48.48"]]